Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.

• DOI: 10.1200/jco.1996.14.2.467
• Publication Date: 2017-02-24T09:46:37Z
• Authors: O Feugeas; N Guriec; A Babin-Boilletot; L Marcellin; P Simon; S Babin; A Thyss; P Hofman; P Terrier; C Kalifa; M Brunat-Mentigny; L M Patricot; F Oberling
• Keywords: Adult; 0301 basic medicine; Heterozygote; Osteosarcoma; Adolescent; Base Sequence; Molecular Sequence Data; Bone Neoplasms; Prognosis; 3. Good health; 03 medical and health sciences; Humans; Genes, Retinoblastoma; Child

PURPOSE The usual therapy of osteosarcoma is neoadjuvant chemotherapy, followed by surgery, then by postoperative chemotherapy. There is no prognostic factor to predict, at diagnosis, the histologic response and final outcome. Inactivation of the retinoblastoma-susceptibility gene RB is associated with the pathogenesis of several human cancers. In primary osteosarcomas, loss of heterozygosity (LOH) at the RB locus has been found in greater than 60% of cases. The aim of this study was to determine the potential early prognostic value of LOH of RB gene on the biopsy material at diagnosis. PATIENTS AND METHODS Forty-seven patients with primary osteosarcoma, treated in four French institutions, were studied. LOH was studied by polymerase chain reaction (PCR) of an informative RB DNA polymorphism. RESULTS Assessment of LOH at the RB gene could be completed on 34 heterozygous patients only. LOH was found in 24 cases (70%). The event-free survival (EFS) rate at 60 months is 100% for patients without LOH, 43% for all patients with RB LOH, and 65% for nonmetastatic patients with RB LOH. The difference in EFS is highly significant at P = .008 and P = .024, respectively. Histologic response after preoperative chemotherapy did not show significant correlation with LOH status. CONCLUSION RB gene LOH appears to be an early predictive feature for osteosarcomas that indicates a potential unfavorable outcome. RB LOH study might shortly help to identify high-risk patients earlier. If this is verified, therapy could then be adapted earlier to the individual's real risk of relapse.